EP3568400B1 - Verfahren zur herstellung von 3-substituiertem 5-amino-6h-thiazolo[4,5-d]pyrimidin-2,7-dion verbindungen - Google Patents

Verfahren zur herstellung von 3-substituiertem 5-amino-6h-thiazolo[4,5-d]pyrimidin-2,7-dion verbindungen

Info

Publication number
EP3568400B1
EP3568400B1 EP18700181.3A EP18700181A EP3568400B1 EP 3568400 B1 EP3568400 B1 EP 3568400B1 EP 18700181 A EP18700181 A EP 18700181A EP 3568400 B1 EP3568400 B1 EP 3568400B1
Authority
EP
European Patent Office
Prior art keywords
acid
compound
formula
hydroxy
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18700181.3A
Other languages
English (en)
French (fr)
Other versions
EP3568400A1 (de
EP3568400C0 (de
Inventor
Junli Chen
Manuel KONRATH
Roland Meier
Yan Ren
Xuemei Wang
Jing XIONG
Jianhua Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP3568400A1 publication Critical patent/EP3568400A1/de
Application granted granted Critical
Publication of EP3568400B1 publication Critical patent/EP3568400B1/de
Publication of EP3568400C0 publication Critical patent/EP3568400C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Definitions

  • the present invention relates to a process for the preparation of a compound of formula (Ia), particularly a compound of formula (I), wherein
  • one object of the invention therefore is to find an efficient synthetic approach which can be applied on a technical scale.
  • C 1-6 alkyl signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 5 carbon atoms, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl and the like.
  • Particular "C 1-6 alkyl” group is methyl or ethyl.
  • halogen signifies fluorine, chlorine, bromine or iodine, particularly fluorine or chlorine.
  • enantiomer denotes two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • diastereomer denotes a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another.
  • salts refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
  • Acid-addition salts include for example those derived from inorganic acids that can be hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids that can be p- toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid.
  • Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, that can be for example, tetramethyl ammonium hydroxide.
  • the chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. It is for example described in Bastin R.J., et al., Organic Process Research & Development 2000, 4, 427-435 ; or in Ansel, H., et al., In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456-1457 .
  • the present invention provides a process for preparing the compounds of formula (X) as outlined in the scheme 1 and compounds of formula (I) as outlined in the scheme 2. wherein R 1 and R 2 are defined as above.
  • the synthesis comprises one or more of the following steps:
  • Step a) the formation of compound (III).
  • Compound (III) is synthesized in the presence of a suitable base in a suitable solvent with sulfonating reagent.
  • the suitable solvent is selected from DCM, CHCl 3 , benzene, THF, 2-MeTHF, fluorobenzene, pyridine, toluene and xylene; particularly the suitable solvent is toluene.
  • the suitable base is selected from TEA, DIPEA, TMPH, MeCy 2 N, NMM, pyridine, K 2 CO 3 , Na 2 CO 3 and Cs 2 CO 3 ; particularly the suitable base is pyridine.
  • the sulfonating reagent is selected from alkylsulfonic anhydride, alkylsulfonic chloride, arylsulfonic anhydride and arylsulfonic chloride, specifically selected from methanesulfonic anhydride, 4-methylbenzenesulfonic anhydride and Tf 2 O; particularly the sulfonating reagent is Tf 2 O.
  • the reaction is performed at -40 °C - 25 °C, particularly at 0°C - 10 °C.
  • Compound (IV) is synthesized in a suitable solvent with reducing reagent.
  • the suitable solvent is selected from benzene, THF, 2-MeTHF, fluorobenzene, xylene and toluene; particularly the solvent is toluene.
  • the reducing reagent is selected from sodium borohydride, lithium borohydride, sodium cyanoborohydride, triacetoxyborohydride and tetraalkyl ammonium borohydride (that can be nBu 4 NBH 4 ), LAH, Red-Al, hydrogenation with Pd/C and Raney Nickle; particularly the reducing reagent is nBu 4 NBH 4 .
  • the reaction is performed at -20 °C - 100 °C, particularly at 65 °C - 75 °C.
  • toluene is used as solvent for step a) in order to telescope step a) and b).
  • the procedure of addition of compound (III) in toluene solution into Bu 4 NBH 4 solution is designed so that it is easy to control the reaction temperature of step b) with higher yield and less by-product.
  • Step c) the formation of the compound (V).
  • Compound (V) is synthesized in the presence of a suitable acid and in a suitable solvent.
  • the suitable solvent is selected from water, a mixture of methanol and water, a mixture of ethanol and water and a mixture of CAN and water; particularly the solvent is a mixture of methanol and water.
  • the suitable acid is selected from HCl, H 2 SO 4 , H 3 PO 4 , MSA, TFA, HCOOH, acetic acid and Lewis acid (that can be iodine), particularly the acid is H 2 SO 4 .
  • the reaction is performed at -5 °C - 50 °C, particularly at 5 °C - 15 °C.
  • Compound (VI) is synthesized in the presence of a suitable base with a suitable acylating reagent and catalyst in a suitable solvent.
  • the suitable acylating reagent is selected from alkylacyl anhydride, alkylacyl chloride, arylacyl chloride, specifically selected from isobutyryl chloride, acetyl chloride, methylbenzoyl chloride and benzoyl chloride; particularly the acylating reagent is benzoyl chloride.
  • the amount of acylating reagent is 1.0-2.0 eq., particularly 1.4-1.5 eq.
  • the suitable catalyst is selected from DMAP, MgCl 2 and Bu 2 SnO; particularly the catalyst is Bu 2 SnO.
  • the amount of catalyst is 0.001-0.2 eq., particularly 0.05 eq.
  • the suitable solvent is selected from DCM, CHCl 3 , THF, 2-MeTHF, toluene and xylene; particularly the solvent is DCM.
  • the suitable base is selected from TEA, DIPEA, NMM, pyridine, Na 2 CO 3 and K 2 CO 3 ; particularly the base is DCM.
  • the reaction is performed at -20 °C- 45 °C, particularly at 0 °C - 10 °C.
  • Compound (VII) is synthesized in the presence of a suitable sulfonating reagent and a suitable base in a suitable solvent.
  • the sulfonating reagent is selected from alkylsulfonic anhydride, alkylsulfonic chloride, arylsulfonic anhydride and arylsulfonic chloride, specifically selected from methanesulfonic anhydride, 4-methylbenzenesulfonic anhydride, MsCl and Tf 2 O; particularly the sulfonating reagent is MsCl.
  • the suitable solvent is selected from DCM, CHCl 3 , benzene, THF, 2-MeTHF, fluorobenzene, pyridine and toluene; particularly the solvent is toluene.
  • the suitable base is selected from TEA, DIPEA, TMPH, MeCy 2 N, NMM, pyridine, K 2 CO 3 , Na 2 CO 3 and Cs 2 CO 3 ; particularly the suitable base is TEA.
  • the reaction is performed at -10°C - 25 °C, particularly at 0 °C -5 °C.
  • Compound (VIII) is synthesized in the presence of a suitable base in a suitable solvent.
  • the suitable base is selected from NaOH, KOH, MeONa, MeOK, t-BuOK and t-BuONa; particularly the base is MeONa.
  • the suitable solvent is selected from a mixture of DCM and methanol, a mixture of DCM and ethanol and a mixture of THF and methanol; particularly the solvent is a mixture of DCM and methanol.
  • the reaction is performed at -10 °C - 25 °C, particularly at 10 °C - 15 °C.
  • the Grignard reagent is selected from MeMgCl, MeMgBr and MeMgI; particularly the Grignard reagent is MeMgCl.
  • the Grignard reagent is added at -70 °C - 30 °C, particularly at - 5 °C - 0 °C.
  • the suitable catalyst is selected from CuCl, CuI and CuBr, particularly the catalyst is CuCl, with amount of 0.05-0.5eq., particularly of 0.05eq.
  • Compound of formula (X) is synthesized in the presence of a suitable acylating reagent with a suitable acid in a suitable solvent.
  • the suitable acylating reagent is selected from alkylacyl anhydride, alkylacyl chloride, arylacyl chloride, specifically selected from AcCl, Ac 2 O; particularly the acylating reagent is Ac 2 O.
  • the acid is selected from TfOH, MSA, TFA, H 2 SO 4 and a mixture of AcOH and H 2 SO 4 ; particularly the acid is a mixture of AcOH and H 2 SO 4 , which is 1-10 wt.% H 2 SO 4 in AcOH solution, particularly 4 wt.% H 2 SO 4 in AcOH solution.
  • the solvent is selected from DCM, CHCl 3 , 2-MeTHF, toluene, IPAc and EtOAc; particularly the solvent is EtOAc.
  • the reaction is performed at -10 °C - 50 °C, particularly at 0 °C - 40 °C.
  • the suitable Lewis acid is selected from TMSOTf and TMSI and HI, particularly the acid is TMSOTf, with the amount of 0.05-1.2eq., particularly 0.05eq.
  • the suitable solvent is selected from DCM, CHCl 3 , benzene, THF, 2-MeTHF, fluorobenzene, xylene, 2,4-dioxane and toluene; particularly the solvent is toluene.
  • Step j) the formation of compound of formula (I) via the hydrolysis of compound of formula (I).
  • Compound of formula (I) is synthesized in the presence of a suitable base in a suitable solvent with or without a phase transfer catalyst.
  • the suitable base is selected from NaOH, KOH, MeONa, MeOK, K 2 CO 3 and NH 3 .H 2 O; particularly the base is K 2 CO 3 .
  • the phase transfer catalyst is selected from PEG-200, PEG-400 and PEG-600; particularly the phase transfer catalyst is PEG-400.
  • the reaction is performed at 0 °C - 45 °C, particularly at 25 °C - 35 °C.
  • Step k the formation of compound of formula (XV).
  • Compound of formula (XV) is synthesized in the presence of a suitable acid in a suitable organic solvent.
  • the suitable acid is selected from D-glutamic acid, L-mandelic acid, 1-hydroxy-2-naphthoic acid, citric acid, 4-aminosalicylic acid, L-tartaric acid, hippuric acid, malonic acid, glutaric acid, oxalic acid, fumaric acid, succinic acid, 4-aminobenzoic acid, 2,5-dihydroxybenzoic acid, L-malic acid, salicylic acid, maleic acid, (1S,3R)-(-)-camphoric acid, pamoic acid, mucic acid, palmitic acid, oleic aicd and lactobionic aicd; particularly the acid is selected from 1-hydroxy-2-naphthoic acid, citric acid, 4-aminosalicylic acid, L-tartaric acid, 2,5-dihydroxybenzoic acid; more particularly the acid is citric acid.
  • the suitable solvent is selected from MeOH, EtOH, n-propanol, IPA, MeCN, acetone, THF, toluene; particularly the solvent is MeCN.
  • an additive can be added to the solvent, wherein the additive is water with volume ratio to solvent (V water /V solvent ) of 0.005-0.015, particularly of 0.005.
  • Step k) is critical for the whole process in terms of purity improvement.
  • step h), i) and j) are telescoped without solid isolation.
  • Typical purity of crude compound of formula (I) is around 75-90%.
  • Different purification and isolation methods were tried.
  • Direct crystallization of the crude compound of formula (I) was tried under various conditions which either give no precipitation or precipitation with low yield.
  • Silicone-gel column purification to upgrade the crude compound purity to 90-95% followed with crystallization gives acceptable yield but this process is unsuitable for technical scale manufacture.
  • formation of compound of formula (XV) with carefully selected acid (that can be citric acid) and solvent system (that can be water and CH 3 CN, V water /V MeCN 0.005) surprisingly gives an efficient and reliable process for technical scale manufacture.
  • the solvent system designed in step k) of present invention gives high yield and good purge effect for impurities.
  • Step l the formation of compound of formula (I) via dissociation from compound of formula (XV).
  • Compound of formula (I) in this step is synthesized via dissociation reaction in the presence of a suitable base in a suitable solvent, followed by a recrystallization procedure.
  • the suitable base used in dissociation reaction is selected from Na 2 CO 3 , K 2 CO 3 , NaHCO 3 , KHCO 3 , NaOH and KOH; particularly the base is Na 2 CO 3 .
  • the suitable solvent used in dissociation reaction is selected from IPAc, EtOAc, MTBE, toluene, THF, 2-MeTHF; particularly the solvent is IPAc.
  • the recrystallization is performed in a suitable solvent at 20 °C -70 °C, particularly at 40 °C - 50 °C, for 2-48 hrs, particularly for 19 hrs.
  • the suitable solvent used in recrystallization procedure is a mixture of water and an organic solvent, wherein the organic solvent is selected from MeOH, EtOH and n-propanol, particularly the organic solvent is EtOH.
  • the suitable weight percentage of organic solvent in water (wt.%) is 0-30wt.%, particularly 7.8 wt.%.
  • the suitable solvent used in recrystallization procedure is a mixture of an polar organic solvent and a non-polar organic solvent; wherein the polar organic solvent is selected from MeOH, EtOH, n-propanol and n-butanol; the non-polar organic solvent is selected from n-heptane and n-hexane; particularly, the solvent used in recrystallization procedure is a mixture of n-propanol and n-heptane.
  • the suitable weight percentage of polar solvent in the solvent mixture is 0-80 wt.%, particularly 60-75 wt.%, more particularly 60 wt.%.
  • the aqueous phase was extracted with 1:1 toluene/n-heptane (600 L, twice).
  • the combined organic phase was washed with 20% NaCl aqueous solution (200 L), then concentrated to form an oil (64.0 kg; 50.4 kg compound (IV) based on assay result) which was used in next step without further purification.
  • the reaction mixture was concentrated to remove all the volatiles and to the left residue was charged with DCM (900 kg), and the resulting organic solution was dried with Na 2 SO 4 (250 kg) for 8 hours.
  • the solid was removed by vacuum filtration and the solution (34.1 kg compound (V) by weight assay) was used for next step without further purification.
  • reaction mixture was filtered through a pad of celite (20 kg) and the organic solution was concentrated under vacuum to re1move all the volatile.
  • the resulting crude mixture was suspended in EtOAc (128 L) and n-heptane (512 L) at 15 °C-25 °C, then heated to 50 °C and stirred for 2 hours.
  • the reaction mixture was then cooled to 10 °C-20 °C over 2 hours and stir at this temperature for 1 hour.
  • the suspension was separated via centrifuge and the wet cake was dried in vacuum oven (30 mmHg, 50 °C) for 18 hours to afford compound (V) (66.5 kg, 69.0% yield).
  • the combined organic phase was washed with 5% NH 3 ⁇ H 2 O aq. solution (7.5 kg), 5% NH 3 ⁇ H 2 O aq. solution (2.5 kg) and 15.6% NaCl aq. solution (30 kg) twice.
  • the organic phase was then concentrated under vacuum to remove all the volatile.
  • To the residue was then charged with n-heptane (5.13 kg), and the resulting mixture was stirred at 50 °C for 30 minutes to form a clear solution, which was slowly cooled to 20 °C-30 °C over 4 hours, and then further cooled to 0 °C-5 °C over 2 hours.
  • the reaction mixture was stirred at 30 °C-35 °C for 30 minutes then cooled to 0 °C-10 °C over 60 minutes, Then Ac 2 O (26.9 kg, 263 mol) and a pre-mixed H 2 SO 4 in AcOH solution (0.356 kg H 2 SO 4 in 8.90 kg AcOH, or 4 wt.% H 2 SO 4 in AcOH) were added at 0 °C-10 °C.
  • the reaction mixture was stirred at 0 °C-10 °C for another 30 minutes then heated to 35 °C-40 °C and maintained at this temperature for 2 hours.
  • the reaction mixture was cooled to 0 °C-10 °C and quenched by adding 20% Na 2 CO 3 aq.
  • reaction mixture was then stirred at 75 °C-80 °C for 2 hours, then TMSOTf (1.12 kg, 5.04 mol, 0.05 eq)) was added, followed by addition of [(3R,5S)-5-[(1S)-1-acetoxypropyl]-3-hydroxy-tetrahydrofuran-2-yl] acetate (15.97 kg, 55.4 mol) in toluene (47 kg) solution over a 45 minutes while keeping the temperature at 75 °C-80 °C.
  • the reaction mixture was stirred at 75 °C-80 °C for 6.5 hours then cooled to 0 °C-10 °C and quenched by adding water (152.4 kg) at 0 °C-10 °C, followed by addition of IPAc (77.4 kg). After phase separation, the aqueous phase was extracted again with IPAc (38.7 kg). The combined organic phase was washed with water (42.6 kg), 15.6% NaCl aq. solution (42.6 kg), and concentrated in vacuum. The residue was dissolved in 2-MeTHF (10.0 kg), then concentrated again, this process was repeated once. The crude product was used in next step without further purification.
  • Compound of formula (XV) or Compound (XVa) is essential to the scale up and quality control of the Compound of formula (I) or (Ia), which requires a comprehensive design for the choice of acid and solvent system to achieve optimized compound recovery and quality.
  • reaction mixture has larger solubility in acetone. So the formation of compound (XVa) with citric acid in MeCN and 1-Hydroxy-2-naphthoic acid in MeCN were chosen for further scale up with purity analysis.
  • reaction mixture was then stirred at 75 °C-80 °C for 2 hours, then TMSOTf (0.254 g, 1.14 mmol, 0.05 eq) was added, followed by addition of [(3R,5S)-2-acetoxy-5-(1-acetoxypropyl)tetrahydrofuran-3-yl] acetate (7.91 g, 27.4 mmol) in toluene (37.2 g) solution over a 30 minutes period while keeping the temperature at 75 °C-80 °C.
  • the mixture was stirred at 75 °C-80 °C for 6.5 hours then cooled to 0 °C-10 °C and quenched by adding water (38 g) at 0 °C-10 °C, followed by addition of IPAc (35.0 g). After phase separation, the aqueous phase was extracted with IPAc (35.0 g). The combined organic phases was washed with water (38.0 g), 15.6% NaCl aq. solution (40.5 g), and concentrated in vacuum. The residue was dissolved in 2-MeTHF (20.6 g), and then concentrated again, this process was repeated once. The crude product was used in next step without further purification.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Claims (13)

  1. Verfahren zur Herstellung einer Verbindung der Formel (I), wobei
    R1 H oder C1-6-Alkyl ist;
    R2 H oder Hydroxy ist;
    umfassend die folgenden Schritte:
    Schritt a) Reagieren einer Verbindung der Formel (II)
    mit einem Sulfonierungsmittel, um eine Verbindung der Formel (III) zu bilden,
    Schritt b) Reagieren einer Verbindung der Formel (III) mit einem Reduktionsmittel, um eine Verbindung der Formel (IV) zu bilden,
    Schritt c) Reagieren einer Verbindung der Formel (IV) mit einer Säure, um eine Verbindung der Formel (V) zu bilden,
    Schritt d) Reagieren einer Verbindung der Formel (V) mit einem Acylierungsmittel und einem Katalysator, um eine Verbindung der Formel (VI) zu bilden,
    Schritt e) Reagieren einer Verbindung der Formel (VI) mit einem Sulfonierungsmittel, um eine Verbindung der Formel (VII) zu bilden,
    Schritt f) Reagieren einer Verbindung der Formel (VII) mit einer Base, um eine Verbindung der Formel (VIII) zu bilden,
    Schritt g) Reagieren einer Verbindung der Formel (VIII) mit einem Grignard-Reagens und einem Katalysator, um eine Verbindung der Formel (IX) zu bilden,
    Schritt h) Reagieren einer Verbindung der Formel (IX) mit einem Acylierungsmittel und einer Säure, um eine Verbindung der Formel (X) zu bilden,
    Schritt i) Reagieren einer Verbindung der Formel (X) mit einer Verbindung der Formel (XI),
    um eine Verbindung der Formel (XII) zu bilden,
    wobei R1 H oder C1-6-Alkyl ist; R2 H oder Hydroxy ist;
    Schritt j) die Bildung einer Verbindung der Formel (I) über die Hydrolyse einer Verbindung der Formel (XII),
    wobei R1 H oder C1-6-Alkyl ist; R2 H oder Hydroxy ist;
    Schritt k) Reagieren einer Verbindung der Formel (I) mit einer Säure, um eine Verbindung der Formel (XV) zu bilden,
    wobei R1 H oder C1-6-Alkyl ist; R2 H oder Hydroxy ist; die Säure ausgewählt ist aus D-Glutaminsäure, L-Mandelsäure, 1-Hydroxy-2-naphthoesäure, Zitronensäure, 4-Aminosalicylsäure, L-Weinsäure, Hippursäure, Malonsäure, Glutarsäure, Oxalsäure, Fumarsäure, Bernsteinsäure, 4-Aminobenzoesäure, 2,5-Dihydroxybenzoesäure, L-Äpfelsäure, Salicylsäure, Maleinsäure, (1S,3R)-(-)-Camphersäure, Pamoasäure, Schleimsäure, Palmitinsäure, Ölsäure und Lactobionsäure;
    Schritt 1) die Bildung einer Verbindung der Formel (I) über Dissoziation einer Verbindung der Formel (XV),
    wobei R1 H oder C1-6-Alkyl ist; R2 H oder Hydroxy ist.
  2. Verfahren nach Anspruch 1, bestehend aus Schritt a) bis Schritt 1).
  3. Verfahren nach Anspruch 1 oder 2, wobei R1 Methyl ist.
  4. Verfahren nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass die Bildung einer Verbindung der Formel (VI) in Schritt d) in Gegenwart einer Base mit einem Acylierungsreagens und einem Katalysator durchgeführt wird, wobei der Katalysator ausgewählt ist aus DMAP, MgCl2 und Bu2SnO.
  5. Verfahren nach Anspruch 4, wobei die Menge des Katalysators 0,001-0,2 Äq., bezogen auf die Verbindung der Formel (V), beträgt.
  6. Verfahren nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass die Bildung einer Verbindung der Formel (X) in Schritt h) in Gegenwart eines Acylierungsreagens mit einer Säure in einem Lösungsmittel durchgeführt wird; wobei das Lösungsmittel ausgewählt ist aus DCM, CHCl3, 2-MeTHF, Toluol, IPAc und EtOAc.
  7. Verfahren nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass die Bildung einer Verbindung der Formel (XV) in Schritt k) in Gegenwart einer Säure in einem organischen Lösungsmittel durchgeführt wird; wobei die Säure ausgewählt ist aus 1-Hydroxy-2-naphthoesäure, Zitronensäure, 4-Aminosalicylsäure, L-Weinsäure, 2,5-Dihydroxybenzoesäure.
  8. Verfahren nach Anspruch 7, wobei das Lösungsmittel ausgewählt ist aus MeOH, EtOH, n-Propanol, IPA, MeCN, Aceton, THF, Toluol.
  9. Verfahren nach Anspruch 8, wobei das Lösungsmittel mit einem Additiv zugegeben wird, wobei das Additiv Wasser ist.
  10. Verfahren nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, dass die Bildung einer Verbindung der Formel (I) über Dissoziation einer Verbindung der Formel (XV) in Schritt 1) in Gegenwart einer Base in einem Lösungsmittel durchgeführt wird, gefolgt von einem Umkristallisationsverfahren; wobei das in dem Umkristallisationsverfahren verwendete Lösungsmittel eine Mischung aus Wasser und einem organischen Lösungsmittel ist, wobei das organische Lösungsmittel ausgewählt ist aus MeOH, EtOH und n-Propanol.
  11. Verfahren nach einem der Ansprüche 1 bis 10, dadurch gekennzeichnet, dass die Bildung einer Verbindung der Formel (I) über Dissoziation einer Verbindung der Formel (XV) in Schritt 1) in Gegenwart einer Base in einem Lösungsmittel durchgeführt wird, gefolgt von einem Umkristallisationsverfahren; wobei das in dem Umkristallisationsverfahren verwendete Lösungsmittel eine Mischung aus einem polaren organischen Lösungsmittel und einem unpolaren organischen Lösungsmittel ist; wobei das polare organische Lösungsmittel ausgewählt ist aus MeOH, EtOH, n-Propanol und n-Butanol; das unpolare organische Lösungsmittel ausgewählt ist aus n-Heptan und n-Hexan.
  12. Verbindung der Formel (XV),
    wobei die Säure ausgewählt ist aus D-Glutaminsäure, L-Mandelsäure, 1-Hydroxy-2-naphthoesäure, Zitronensäure, 4-Aminosalicylsäure, L-Weinsäure, Hippursäure, Malonsäure, Glutarsäure, Oxalsäure, Fumarsäure, Bernsteinsäure, 4-Aminobenzoesäure, 2,5-Dihydroxybenzoesäure, L-Äpfelsäure, Salicylsäure, Maleinsäure, (1S,3R)-(-)-Camphersäure, Pamoasäure, Schleimsäure, Palmitinsäure, Ölsäure und Lactobionsäure; insbesondere die Säure ausgewählt ist aus 1-Hydroxy-2-naphthoesäure, Zitronensäure, 4-Aminosalicylsäure, L-Weinsäure, 2,5-Dihydroxybenzoesäure; und insbesondere die Säure Zitronensäure ist;
    R1 H oder C1-6-Alkyl ist;
    R2 H oder Hydroxy ist.
  13. Verbindung nach Anspruch 12, wobei die Verbindung [(1S)-1-[(2S,4R,5R)-5-(5-Amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl]acetat-Zitronensäure ist.
EP18700181.3A 2017-01-06 2018-01-04 Verfahren zur herstellung von 3-substituiertem 5-amino-6h-thiazolo[4,5-d]pyrimidin-2,7-dion verbindungen Active EP3568400B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017070437 2017-01-06
CN2017112149 2017-11-21
PCT/EP2018/050159 WO2018127525A1 (en) 2017-01-06 2018-01-04 PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS

Publications (3)

Publication Number Publication Date
EP3568400A1 EP3568400A1 (de) 2019-11-20
EP3568400B1 true EP3568400B1 (de) 2025-11-19
EP3568400C0 EP3568400C0 (de) 2025-11-19

Family

ID=60953862

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18700181.3A Active EP3568400B1 (de) 2017-01-06 2018-01-04 Verfahren zur herstellung von 3-substituiertem 5-amino-6h-thiazolo[4,5-d]pyrimidin-2,7-dion verbindungen

Country Status (11)

Country Link
US (1) US11142534B2 (de)
EP (1) EP3568400B1 (de)
JP (2) JP7201598B2 (de)
KR (1) KR102602328B1 (de)
CN (1) CN110139868B (de)
AU (2) AU2018205994B2 (de)
CA (1) CA3048768A1 (de)
IL (1) IL267801B2 (de)
MX (1) MX384745B (de)
TW (1) TWI808068B (de)
WO (1) WO2018127525A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3568400B1 (de) * 2017-01-06 2025-11-19 F. Hoffmann-La Roche AG Verfahren zur herstellung von 3-substituiertem 5-amino-6h-thiazolo[4,5-d]pyrimidin-2,7-dion verbindungen
CN110167947B (zh) * 2017-01-06 2022-05-03 豪夫迈·罗氏有限公司 乙酸[(1S)-1-[(2S,4R,5R)-5-(5-氨基-2-氧代-噻唑并[4,5-d]嘧啶-3-基)-4-羟基-四氢呋喃-2-基]丙基]酯的固体形式
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2025032082A1 (en) 2023-08-08 2025-02-13 F. Hoffmann-La Roche Ag Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
FR2668153B1 (fr) * 1990-10-22 1995-03-31 Pasteur Merieux Serums Vacc Nouveaux composes ribonucleosides, leur procede de preparation et les medicaments les contenant.
WO1998016184A2 (en) 1996-10-16 1998-04-23 Icn Pharmaceuticals, Inc. Purine l-nucleosides, analogs and uses thereof
EP1072607A3 (de) 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purin-L-Nukleoside, deren Analoga und Verwendungen
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
PL1824482T3 (pl) 2004-12-17 2014-07-31 Anadys Pharmaceuticals Inc 3,5-Dipodstawione oraz 3,5,7-tripodstawione związki 3H-oksazolo- oraz 3H-tiazolo[4,5-d]pirymidyn-2-onowe i ich proleki
DE602006015700D1 (de) 2005-11-21 2010-09-02 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
BRPI0713680A2 (pt) 2006-06-22 2012-10-23 Anadys Pharmaceuticals Inc composto, composição farmacêutica e métodos de modulação das atividades imuno da citocina, de tratamento de infecção de vìrus da hepatite c em paciente e de tratamento de desordem de proliferação relacionada em mamìfero carecido do mesmo
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
BRPI0717741A2 (pt) 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
US20110166092A1 (en) 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
BR112017011941B1 (pt) 2014-12-08 2023-02-28 F. Hoffmann-La Roche Ag Compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona 3-substituídos para o tratamento e profilaxia de infecção viral
UA123670C2 (uk) * 2015-03-16 2021-05-12 Ф. Хоффманн-Ля Рош Аг Комбіноване лікування агоністом толл-подібного рецептора (tlr7) і інгібітором збирання капсиду вірусу гепатиту в
EP3294746B1 (de) 2015-05-12 2021-10-06 F. Hoffmann-La Roche AG Substituierte aminothiazolopyrimidindionderivate zur behandlung und prophylaxe von virusinfektionen
EP3317289B1 (de) 2015-06-30 2021-10-27 F. Hoffmann-La Roche AG Neuartiges substituiertes aminothiazolpyrimidindion zur behandlung und prophylaxe einer virusinfektion
EP3568400B1 (de) * 2017-01-06 2025-11-19 F. Hoffmann-La Roche AG Verfahren zur herstellung von 3-substituiertem 5-amino-6h-thiazolo[4,5-d]pyrimidin-2,7-dion verbindungen

Also Published As

Publication number Publication date
TWI808068B (zh) 2023-07-11
MX2019008116A (es) 2019-09-04
IL267801A (en) 2019-09-26
WO2018127525A1 (en) 2018-07-12
CN110139868A (zh) 2019-08-16
TW201829419A (zh) 2018-08-16
AU2018205994B2 (en) 2021-09-09
KR102602328B1 (ko) 2023-11-16
US20200024287A1 (en) 2020-01-23
EP3568400A1 (de) 2019-11-20
JP2020504126A (ja) 2020-02-06
AU2021258083A1 (en) 2021-11-25
IL267801B2 (en) 2023-07-01
KR20190099492A (ko) 2019-08-27
AU2018205994A1 (en) 2019-06-13
IL267801B1 (en) 2023-03-01
BR112019013884A2 (pt) 2020-03-03
JP2023011699A (ja) 2023-01-24
MX384745B (es) 2025-03-14
CN110139868B (zh) 2021-07-09
JP7201598B2 (ja) 2023-01-10
CA3048768A1 (en) 2018-07-12
US11142534B2 (en) 2021-10-12
EP3568400C0 (de) 2025-11-19

Similar Documents

Publication Publication Date Title
EP3568400B1 (de) Verfahren zur herstellung von 3-substituiertem 5-amino-6h-thiazolo[4,5-d]pyrimidin-2,7-dion verbindungen
KR102366697B1 (ko) 마크로시클릭 hcv ns3 억제 트리펩티드의 합성
US8846896B2 (en) Methods of preparing substituted nucleotide analogs
JP2020523381A (ja) ３’−デオキシアデノシン−５’−ｏ−［フェニル（ベンジルオシキ−ｌ−アラニニル）］ホスフェート（ｎｕｃ−７７３８）の合成
JP2017522343A (ja) ホスホルアミデート類の合成
US9624258B2 (en) Polymorph of regadenoson
JP2020070296A (ja) リナグリプチンの製造法
WO2025032082A1 (en) Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
JP7379381B2 (ja) リナグリプチンおよびその塩の製造のための中間体およびプロセス
HK40012866A (en) Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
HK40012866B (en) Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
KR101628946B1 (ko) 실로도신의 개선된 제조방법
BR112019013884B1 (pt) Processo para a preparação de compostos de 5 -amino -6h´ -tiazolo [4,5 -d] pirimidina -2,7 -diona 3 -substituídos
JP2016172755A (ja) 抗ウイルス化合物およびその有用な中間体の調製方法
US20090018325A1 (en) Process for preparing l-nucleic acid derivatives and intermediates thereof
WO2024184926A1 (en) Process for preparation of chiral ruxolitinib and salts thereof
JP2026502847A (ja) Ｎｌｒｐ３阻害剤の調製のためのプロセス
WO2022254457A1 (en) An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
WO2021260498A1 (en) An improved purification process for the preparation of ertugliflozin and ertugliflozin l-pyroglutamic acid co-crystal
HK1217493A1 (zh) 製備抗病毒組合物的方法及其中間體的應用
CN102464691A (zh) 制备抗病毒组合物的方法及其中间体的应用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190806

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210512

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250617

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: F10

Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251119

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20251119

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20251125

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251220

Year of fee payment: 9

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 9

Effective date: 20251217

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260201